Effect of Mexiletine on Cortical Hyperexcitability in Sporadic Amyotrophic Lateral Sclerosis (SALS)
Study Purpose:
The purpose of this study is to find out whether the drug mexiletine will be effective in lowering motor neuron electrical activity in the brains and nerves in the arms of people with ALS.
Disease:
Amyotrophic Lateral Sclerosis (ALS), Sporadic ALSStudy Type:
Interventional TrialStudy Category:
Drug TrialStudy Status:
Not enrollingPhase:
Phase IIStudy Chair(s)/Principal Investigator(s):
Michael Weiss, MD, Washington University
Clinicaltrials.gov ID (11 digit #):
NCT02781454Neals Affiliated?
YesCoordinating Center Contact Information
MGH - NCRIDavid Klements, MS / .(JavaScript must be enabled to view this email address) / 617-726-3430
Emily Engel / .(JavaScript must be enabled to view this email address) / 617-724-7210
165 Cambridge Street
6th Floor
Boston, Massachusetts 02114 United States
Full Study Summary:
The purpose of this research study is to find out whether the drug mexiletine will be effective in lowering motor neuron electrical activity in the brains and nerves in the arms of people with ALS. The investigators will also determine if there are any signs that the drug may slow down the progression of ALS and reduce muscle cramps and muscle twitching. This will be determined through transcranial magnetic stimulation (TMS) and threshold tracking nerve conduction studies (TTNCS). In this trial, the participants will be taking either 300mg/day of mexiletine, 600mg/day of mexiletine, or placebo (non-active study drug).
Study Sponsor:
ALSA; ALSFACParticipant Duration:
8 Weeks